Abbott Q4 sales misses analyst expectations, hurt by diagnostics unit's challenges
I'm PortAI, I can summarize articles.
Abbott's Q4 sales rose 4.4% but fell short of analyst expectations, with adjusted EPS meeting forecasts at $1.50. The diagnostics unit faced challenges, leading to a 2.5% sales decline. The company announced plans to acquire Exact Sciences, expected to close in Q2 2026, and projects 2026 organic sales growth of 6.5% to 7.5%. The average analyst rating remains "buy," with a 12-month price target of $145.00, reflecting a 20.1% upside from its recent trading price of $120.73.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments